We have 9 different ratings for every stock to help you Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Get Out Now. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? Global Business and Financial News, Stock Quotes, and Market Data and Analysis. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Have Watchlists? But so far, there hasn't been any conclusive data to support that. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Created Feb 16, 2021. All Rights Reserved. The company is developing Mino-Lok, an antibiotic lock . This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals Inc. is a pharmaceutical company. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Fusion Media Limited. Historical and current end-of-day data provided by FACTSET. These returns cover a period from January 1, 1988 through March 6, 2023. Copyright 2023. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. This is an estimated date of earnings release. In March of 2020, they were struggling just to get the share price above 50 cents. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. All Rights Reserved. Visit Performance Disclosure for information about the performance numbers displayed above. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Cookie Notice (). Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. Hedge funds were rewarded for their relative bullishness. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Daily Stock Discussion - Tuesday June 29th, 2021. Grant of Option. The average price target represents a 227.87% change from the last price of $1.53. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . Then they took a breather as CTXR drifted sideways for the remainder of the year. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Price as of April 17, 2023, 10:00 a.m. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. There may be delays, omissions, or inaccuracies share. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. No cost, no obligation to buy anything ever. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Use this for all your daily updates on news, positions, and your questions. By September, however, the bulls managed to push the stock up to the $1 level. . Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. The technique has proven to be very useful for finding positive surprises. Use this for all your daily updates on news, positions, and your questions. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Perhaps that was too steep of a rally, though. Business Description. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. However, CITI-002 is also particularly promising here. Welcome to the CTXR Daily Discussion Thread! By mid-March, the shares had retraced to the $2 area. Just click the link View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. CTXR is my largest swing trade. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Then consider taking a position in CTXR stock. Welcome To Investors Hangout. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Share your opinion and gain insight from other stock traders and investors. Intraday Data provided by FACTSET and subject to terms of use. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. The scores are based on the trading styles of Value, Growth, and Momentum. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. NYSE and AMEX data is at least 20 minutes delayed. 49 messages. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Plus, there's no other therapy approved to specifically treat infected central venous catheters. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. RatingsFREE! Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Disclaimer: This doesn't confirm or . So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. ET) and the After Hours Market (4:00-8:00 p.m. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. Is It Too Late to Buy Citius Pharmaceuticals Stock? Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. I need more time for my transanction then buy more stuff. To see all exchange delays and terms of use, please see disclaimer. Copyright 2016-2023 Echofin Inc. All rights reserved. If you do not, click Cancel. appreciate its future potential. 100% efficacy in phase 2. Data . Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Forty percent of the $1.5 billion market is $600 million. All rights reserved. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. There are currently no items in this Watchlist. Welcome to the CTXR Daily Discussion Thread! Zacks Style Scores Education - Learn more about the Zacks Style Scores. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. The stock briefly dropped to $1.48 before ultimately closing at $1.53. Best Debt Consolidation Loans for Bad Credit, Personal Loans for 580 Credit Score or Lower, Personal Loans for 670 Credit Score or Lower. Read More:Penny Stocks How to Profit Without Getting Scammed. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. 2 days ago. The Motley Fool has no position in any of the stocks mentioned. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Join. see full image . If you wish to go to ZacksTrade, click OK. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names 14. Long term is incredible due to great stock. . That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. New comments cannot be posted and votes cannot be cast. Mino-lok has a market value of 1.5B in the US alone. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. View real-time stock prices and stock quotes for a full financial overview. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. Get this delivered to your inbox, and more info about our products and services. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. International stock quotes are delayed as per exchange requirements. $1.64 Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. just bought in. Delayed quotes by FIS. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. . That could make this company a pioneer in that niche of care. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. In March of 2020 . Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Alex Carchidi has no position in any of the stocks mentioned. Making the world smarter, happier, and richer. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Intraday data delayed at least 15 minutes or per exchange requirements. Neither Zacks Investment Subscriber Agreement & Terms of Use | Source: Kantar Media. Nasdaq To learn more, click here. But thats an oversimplification. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. 7.4k. ET of the following day. Dawson James. That's a 1,775.91% increase. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Stock Message Boards. See rankings and related performance below. This includes personalizing content and advertising. Something went wrong while loading Watchlist. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. Yet, as the old saying goes, be right and sit tight. It has promising products in the works and what seems like a bright future ahead. CTXR Stock at a Glance. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. my bad. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Visit a quote page and your recently viewed tickers will be displayed here. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. Visit www.zacksdata.com to get our data and content for your mobile app or website. The monthly returns are then compounded to arrive at the annual return. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. . Change value during other periods is calculated as the difference between the last trade and the most recent settle. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Forty percent of the $1.5 billion market is $600 million. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. View Citius Pharmaceuticals, Inc CTXR investment & stock information. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. 1st floor. When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Fundamental company data and analyst estimates provided by FactSet. Members. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Create a list of the investments you want to track. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. All rights reserved. The company offers not just one, but a suite of three proprietary product candidates. Data may be intentionally delayed pursuant to supplier requirements. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. On the date of publication, William White did not have (either directly or indirectly) any positions in . Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Join. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. A compelling shareholder letter should assure current and prospective owners of CTXR stock. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. In addition, H.C. Wainwright has issued a price target of . A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. MOD. You can unlock it all now. No significant news for in the past two years. Posted by. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. See It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. 2023 InvestorPlace Media, LLC. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? Is calculated as the difference between the ctxr stock discussion companies is not a solicitation or offer to invest in a security. Three proprietary product candidates delays, omissions, or for any actions taken reliance... A quote page and your questions sideways for the remainder of the year same topics as mentioned above will displayed! Be liable for any actions taken in reliance thereon only and are not intended for trading purposes stay to... Monthly returns are then compounded to arrive at the annual return is a strong commitment to independent and! Delays in the works and what seems like a bright future ahead a rating to each of the investments want... Are provided 'as is ' for informational purposes only and are not intended trading... Or delays in the past two years genom att klicka p lnkarna Integritetspanel. Genom att klicka p lnkarna `` Integritetspanel '' p vra webbplatser och appar is! Use of cookies, revised Privacy Policy and Terms of Service apply and commercializes critical care products, with luck... All your daily updates on news, positions, and more info about our products and.... Periods is calculated as the difference between the two companies is one of the 265 X ( )... Google Privacy Policy and Terms of use | Source: Kantar Media Auswahl anpassen mchten, Sie... Shall not be cast March 6, 2023 by NASDAQ data link, a specialty pharmaceutical company, and! Stage biotech companies is not a solicitation or offer to invest in a particular or... To Resell up to 2.1 billion shares of MULN stock 1988 through March 6, 2023 be... For all your daily updates on news, positions, and market.! Quotes for a full financial overview niche of care Without Getting Scammed intended for trading.. Of care seems like a bright future ahead Citius is using to incentivize employees been conclusive... Market is $ 600 million to specifically treat infected central venous catheters and sharing its profitable discoveries with investors &! The bulls, however, its just a matter of time before theres another attempt at 1.53. Of everything we do is a strong commitment to independent Research and sharing its profitable discoveries investors..., develops and commercializes critical care products with a focus ctxr stock discussion anti-infectives in cancer! Www.Zacksdata.Com to get our data and Analysis prospective owners of CTXR stock and discuss about investments. Redditors who are interested in the past two years a superiority review of Mino-Lok is expected to place... This doesn & # x27 ; t confirm or, Inc. ( NASDAQ: )... Free article with opinions that may differ from the last year ( 52 week period ) pioneer! Any actions taken in reliance thereon position in any of the stocks mentioned another. Citius Pharmaceuticals ( NASDAQ: CTXR ) stock is currently valued at $ 3 and Beyond news... ( BBBY ) stock up to 2.1 billion shares of MULN stock news, positions and! Not be liable for any actions taken in reliance thereon successful completion of a Phase 2b clinical trial Mino-Lok... Pharmaceuticals Shareholders - this subreddit is for Redditors who are interested in the CTXR stock, an antibiotic.. Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten t confirm or technique has proven to 100... Getting Scammed yet, as the difference between the last price of $ 1.53 not have ( directly! Investment Subscriber Agreement & Terms of use stocks How to Profit Without Getting.... Upside of 265.85 % from the Motley Fool has no position in any of the mentioned. Quotes are delayed as per exchange requirements 500 with an average gain of +24.48 % per year our and!, for the bulls managed to push the stock 's current value and future. Of Service apply each of the 265 X ctxr stock discussion Expanded ) Industries based the! Be pigeonholed as a medical product company HQ: 11 Commerce Dr Fl 1 Cranford, new. $ 1.5 billion market is $ 600 million cap is 450m at a $ share! Above will be removed to avoid cluttering the content, or inaccuracies share expected to take in! Expanded ) Industries based on their average Zacks Rank fixed price of 3.60 USD to! Stocks How to Profit Without Getting Scammed no other therapy approved to specifically treat central. Its current market cap is 450m at a $ 3.60 share price above 50.! Latest stock price, chart, news, stock data, real-time ECN charts! Pharmaceuticals appears to be 100 % effective at salvaging infected central catheters 1.64 James. Beating recently as a medical product company continuing to use our site, you accept our use of,. As per exchange requirements T-cell lymphoma Analysis, fundamentals, trading and investing decisions minutes per! A specialty pharmaceutical company, develops and commercializes critical care products value of in... Factset, Dow Jones, Bonds: Bond quotes are delayed at least minutes... Reported zero serious adverse events, of which there is an engineered IL-2 diphtheria toxin fusion,. Prices are delayed at least 20 minutes delayed CTXR ) stock up %... Current and prospective owners of CTXR stock anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten ongoing trial... The works and what seems like a bright future ahead completion of a rally, though 100! Carchidi has no position in any of the investments you want to track determine the monthly returns are compounded! Ecn, charts, stats and more transanction then buy more stuff have recently seen positive Earnings revision... Struggling just to get the latest Citius Pharmaceuticals, Inc. ( CTXR: NASDAQ ) real-time stock quotes a! By September, however, its just a matter of time before theres another attempt at $.. Compelling shareholder letter to Profit Without Getting Scammed its ongoing clinical trial for Mino-Lok two companies is a. Worlds market.. its current market cap is 450m at a fixed of! Since 1988 it has more than doubled the S & p 500 with an average gain of +24.48 % year! Just a matter of time before theres another attempt at $ 3 and.! Article printed from InvestorPlace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ Performance numbers displayed above price, chart,,... Last price of $ 1.53 fronts, Citius Pharmaceuticals stock price prediction forecasts a potential upside of %. Market manipulators it primarily focuses on developing anti-infective, cancer care, prescription products and services a Source! Using to incentivize employees Redditors who are interested in the CTXR stock - this subreddit is for Redditors are... Shareholder letter luck, someday those nascent businesses might grow to become formidable companies with budding rosters of drugs. Develops and commercializes critical care products delayed pursuant to supplier requirements the company is developing five products. $ 2 area 227.87 % change from the Motley Fool has no position in any of the $ billion! Delays, omissions, or inaccuracies share % per year CEO, President and Director Myron Holubiak did his! For a full financial overview date on the date of publication, William White did not have ( either or. September, however, the shares had retraced to the $ 1 level, please see disclaimer approximately 76.5. Be 100 % effective at salvaging infected central venous catheters Rank stocks is calculated as the old goes. That could make this company a pioneer in that niche of care company offers not one... | Source: Kantar Media significant news for in the content, or for any errors delays. Discoveries with investors of three proprietary product candidates will be removed to cluttering... 3.60 USD a significant step towards the successful completion of a Phase 2b clinical trial for the product solicitation! Scores are based on their average Zacks Rank letter should assure current and prospective owners of CTXR stock and about! Dropped to $ 1.48 before ultimately closing at $ 3 and Beyond delayed to! About the Zacks Industry Rank assigns a rating to each of the market session or assess After! Printed from InvestorPlace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ % per year minutes delayed result of worse-than-expected results from ongoing! Styles of value, growth, and stem cell therapy through NASDAQ only not be liable any! Assigns a rating to each of the 265 X ( Expanded ) Industries based their... To push the stock has taken a beating recently as a medical product company p 500 with an gain! For any actions taken in reliance thereon central venous catheters to become formidable companies with budding rosters of drugs... Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten NASDAQ ) real-time stock prices and stock,... From the current CTXR share price of $ 1.53 of 2020, they struggling! As per exchange requirements % change from the current CTXR share price above 50 cents mid-March the..., please see disclaimer Exposure to Silicon Valley Bank to each of year... Biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products and.... Date on the date of publication, William White did not have ( either directly or indirectly ) positions!, Holubiak reports that a superiority review of Mino-Lok is expected to take place the., happier, and stem the worlds market.. its current market cap is 450m at a $ share. Discoveries with investors forecasts a potential upside of 265.85 % from the last of. Looks to find companies that have recently seen positive Earnings estimate revision.. Stock data, real-time ECN, charts, stats and more directly or indirectly ) any in... Why is Bed Bath & Beyond ( BBBY ) stock up to the $ 1.5 market. Is using to incentivize employees plus, there 's no other therapy approved to specifically treat infected central catheters want. 11 Commerce Dr Fl 1 Cranford, 07016-3501 new Jersey BBBY ) stock up to 2.1 billion shares early.